NASDAQ
0.60USD
+0.01 (+1.56%)
We have scored 10 news catalysts on Fractyl Health, Inc. (GUTS) over the past 12 months. The biggest single-day move next to one of them came Aug 22, 2026, when GUTS closed +13.9%: “Stockholder Alert: Robbins LLP Informs Investors of the Fractyl Health, Inc. Class Action”. Coverage across the window leans negative (average ticker sentiment −0.64). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
95.2M
P/E
—
EPS
—
Beta
2.33
52W range
0.377-2.445
Day range
0.59–0.60
Open
0.59
Prev close
0.59
Volume
1.8M
Avg volume
1.8M
Dividend
0.00
IPO
2024-02-02
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Fractyl Health, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for GUTS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
